Virus inactivation is critical in the purification of biotherapeutics. Triton X-100 is the most used detergent for virus inactivation in monoclonal antibodies, plasma industry, and bacterial cell lysis. However, Triton X-100 has been categorized as a hazardous chemical due to its strong endocrine effects after it biodegrades. It has gained attention and will be prohibited from manufacturing by the European Regulation (REACH). Considering REACH's recommendations and health concerns, Merck has limited production of Triton X-100 with authorization from REACH and will discontinue over a period of time. To provide an alternative and help existing users of Triton X-100, we have developed Deviron C16, a sustainable product to replace Triton-X100. Deviron C16 has shown great performance and is as effective as Triton™ X-100 in the inactivation of viruses.
In this webinar, you will learn about:
Field Marketing Specialist
Satish has more than 15 years of experience in research, sales, sales development, field marketing, and technology management. He is an expert in cell line development, upstream process development using E. coli, and CHO platforms for expressing biotherapeutics and biosimilars. For the past 6 years, he has worked with the Technical University Munich, Hetero, Aurobindo, and others associated with Merck, supporting our bioprocess business in India. Sateesh holds a double master's, one in biotechnology from Bangalore University and one in molecular biology from the University of Skovde, Sweden.
Pharma and biopharma manufacturing
Session 1:presented August 9, 2022
To continue reading please sign in or create an account.Don't Have An Account?